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Abstract: Streptococcus suis (S. suis) is an emerging zoonotic pathogen, demonstrated as an etiological
agent in human infections in increasing frequency, including diseases like purulent meningitis, sepsis,
uveitis-endophtalmitis and arthritis. Due to the increased availability and utility of novel diagnostic
technologies in clinical microbiology, more studies have been published on the epidemiology of S. suis,
both in veterinary and human medicine; however, there are no comprehensive data available regarding
human S. suis infections from East-Central European countries. As a part of our study, data were
collected from the National Bacteriological Surveillance (NBS) system on patients who had at least one
positive microbiological result for S. suis, corresponding to an 18-year study period (2002–2019). n = 74
S. suis strains were isolated from invasive human infections, corresponding to 34 patients. The number
of affected patients was 1.89 ± 1.53/year (range: 0–5). Most isolates originated from blood culture
(63.5%) and cerebrospinal fluid (18.9%) samples. Additionally, we present detailed documentation of
three instructive cases from three regions of the country and with three distinctly different outcomes.
Hungary has traditional agriculture, the significant portion of which includes the production and
consumption of pork meat, with characteristic preparation and consumption customs and unfavorable
epidemiological characteristics (alcohol consumption, prevalence of malignant diseases or diabetes),
which have all been described as important predisposing factors for the development of serious
infections. Clinicians and microbiologist need to be vigilant even in nonendemic areas, especially if
the patients have a history of occupational hazards or having close contact with infected pigs.
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1. Introduction
Streptococcus suis (S. suis) is an emerging zoonotic pathogen, which has been demonstrated as
an etiological agent in human infections in increasing frequency [1,2]. The clinical presentations of
these—often serious or life-threatening—infections may be wide-ranging, including syndromes such as
purulent meningitis, sepsis, streptococcal toxic shock-like syndrome (STSLS), uveitis-endophthalmitis
and arthritis; nevertheless, S. suis has also been described as an opportunistic pathogen of lower
respiratory tract infections (e.g., pneumonia) [3–5]. In recent years, due to the increased availability and
utility of novel diagnostic technologies and molecular biological methods both in veterinary and human
clinical microbiology, more studies have been published on this zoonotic infectious entity, including
the epidemiology of human infections and the virulence factors of this pathogen [6,7]. The bacterium
has been described as a colonizing agent in the upper respiratory, gastrointestinal tract, and genital
organs of various animals (pigs, ruminants, cats, dogs, horses and other wild animals). S. suis was first
reported in 1954 by veterinarians after outbreaks of septicemia and/or meningitis and purulent arthritis
occurred among piglets [8–10]. Fourteen years later, some human S. suis cases were first described
in Denmark [11]. So far, over 1600 human cases have been reported in the literature worldwide,
although this infection is probably severely underdiagnosed [1,2,12]. Subsequently, the number of
human S. suis cases reported has increased over the past few years, with the highest prevalence rate in
Southeast Asia, where there is a high rate of pig meat consumption: the majority of these infections
originated from Thailand (~36%), Vietnam (~30%) and China (~22%); therefore, Thailand and Vietnam
have the highest disease prevalence stratum globally, with estimated 0.82 and 0.54 cases/100,000
population, respectively [13,14]. In contrast, the prevalence in Western European countries ranges
between 0.01–0.10 cases/100,000 population (with highest prevalence in the Netherlands and the
UK) [1,4]. The epidemiological situation in Australasia is similar to the one on the European continent,
while the Americas and Japan has reported the lowest prevalence of human S. suis cases (<1% of global
cases) [1–4]. The clinical relevance of these invasive infections must not be underestimated; based on
the results of a meta-analysis, the mortality rate associated with these infections is 12.8% (confidence
interval: 9.0%–18.0%), with notable geographical differences observed among geographical regions
(Asia: up to 26%, Western countries: 2–4%); in addition, almost half of the patients experience some
kind of neurological sequelae after recovery [4].
These bacteria are facultatively anaerobic Gram-positive, ovoid or coccal bacilli, with sizes on
average between 1.0 to 1.5 µm, appearing in pairs, short chains or as single bacteria [15]. The bacterial
species is genetically and phenotypically very heterogeneous, which were earlier classified into the
Streptococcus Lancefield groups R, S, and T [16]. Currently, S. suis is classified within the family
Streptococcaceae, order Lactobacillales, phylum Firmicutes [17]. The bacterial virulence-associated
factors may be classified into the following sub-groups (of note, some genes probably may be
classified into more than one categories due to their dual characteristics): (i) surface/secreted elements;
(ii) protease enzymes; (iii) transcription factors/regulatory systems and (iv) other virulence determinants
(transporters/secretion systems) [18]. The list of confirmed and putative virulence factors is extensive,
but the most prominent and best-characterized virulence factors of clinical S. suis strains are surface and
secreted elements: capsular polysaccharides, extracellular factor (EF; epf ), muramidase-released protein
(MRP; mrp) and a 38-kDa surface protein, suilysin (SLY) [19–22]. S. suis isolates are included a complex
population consisting of heterogeneous strains and they may be classified into 35 serotypes (1–34,
1/2) to date, based on the principal virulence factor, the capsular polysaccharide antigen (CPS) [23,24].
Human S. suis cases are reported to be mainly due to serotype 2 (SS2) (24.3–74.7%) and 14 (2.0–13.0%),
with both serotypes being equally implicated in cases of meningitis (50–70%) and sepsis (20–25%) [4,25].
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SS2 is believed to be the most virulent type, with a polymorphic mosaic genome, which is associated
with a higher virulence and is frequently isolated from humans affected by these infections [26].
The occurrence of serotype 14 infections was sporadically reported in Northern Thailand, Vietnam
and case reports were also described in the UK, France, Australia, and Canada [27,28]. In constrast,
serotype 9 is one of the most common (19.4–61.0%) in the pigs of some Western European countries [29].
Infections caused by serotypes 4,5,8,9,11,12,13,16,21,24,31 and species with untypeable serotypes are
considered to be rare (0–2.7%)—only sporadic cases were reported [4,30–35]. S. suis isolates causing
streptococcal toxic shock syndrome (STSS) and high mortality rates were associated with the presence
of a pathogenicity island (89K PAI), most commonly seen in large Chinese outbreaks [36].
There are some typical risk factors for acquiring S. suis infections such as raw (or uncooked) pork
consumption, direct exposure to pigs or pork, workplace exposure in several professions (e.g., butchers,
slaughterhouse workers, hunters, retail workers in butcheries), excessive consumption of alcohol,
skin injuries (especially during handling pig or pork), male gender and some underlying diseases
contributing to immuno-compromised conditions [37,38]. Most patients, who were infected by
serotypes other than SS2, had liver cirrhosis [30,34] or other pre-existing immunosuppressive states [39].
In addition, as previously reported for invasive Group B Streptococcus infections, alcoholism, diabetes
mellitus, splenectomy and malignancies have been suggested as important predisposing factors for the
development of rapid and fatal S. suis infections [40]. In humans, the intestinal route of infection seems
to be an important port of entry, after consumption of fresh/raw contaminated pork meat (e.g., in some
Southeast Asian countries) [41]. In fact, the epidemiology of human infections may be significantly
affected by the cultural differences and eating habits between the Asian and the European/American
regions, while this also raises concerns regarding imported cases due to increasing levels of tourism
towards Asia [1–5]. Apart from the handling or ingestion of pork meat, direct contact with the mucous
membranes of pets (cats, dogs), livestock (horses, ruminants) and wild animals (deer, wild boar) may
also be an important source of infection [37,38]. To date, human-to-human transmission has not been
demonstrated to occur. Nevertheless, the transmission of bacteria through skin abrasions was also
believed to be an important route of infection, altough skin injuries in patients during exposure or
before infection were noted only in some studies [42]. Earlier studies suggest that sometimes humans
could be healthy carriers of S. suis as well [43–45]. Encapsulated S. suis strains are highly invasive
pathogens; after penetration of host mucosal barriers, these bacteria may reach and survive in the blood
cells and they may subsequently invade different organs, such as liver, kidney, spleen, lung and even the
heart [46]. Pathogenic strains are able to cross the brain microvascular endothelial cells (BMECs) and/or
the epithelial cells of the choroid plexus at the blood–brain barrier (BBB) and/or the blood–cerebrospinal
fluid barrier to gain access to the central nervous system (CNS) [43,47–49]. After an incubation period
that ranges from a few hours to a few days in humans, S. suis infections result in meningitis, sepsis,
pneumonia, endocarditis or peritonitis [1,2,12,43,50,51]. In addition, peracute infections with shock
and a high mortality rate have been described, particularly in the case of streptococcal toxic shock-like
syndrome (STSLS) [52].
Around 8–10% of cases worldwide were reported from the European continent; however, to date,
there are no comprehensive epidemiological data available in the literature regarding human S. suis
infections from East-Central European countries [4,15,53]. The aim of our present study was to report
on the emergence and clinical manifestations of S. suis infections in Hungary over a long surveillance
period—using data from the national bacteriological database—in addition to illustrating the various
possible clinical outcomes of human S. suis infections through the description of instructive cases from
various Hungarian clinical centers.
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2. Materials and Methods
2.1. Study Site and Population
Hungary is a medium-sized, landlocked country in East-Central Europe, with a total area of
93,030 km2 and a population of 9,772,756 persons (estimated from the most recent census data;
population density: 105.1/km2) [54]. The area of Hungary may be divided into 7 regions or 19 counties
(in addition to the capital of Budapest) for administrative purposes. Based on Organisation for
Economic Co-operation and Development (OECD) guidelines, Hungary is a high-income country (with
the 54th largest global economy based on nominal gross domestic product (GDP) and 45th highest
Human Development Index (HDI)) [55]. The average life expectancy in Hungary is 72.4 years for
males and 79.0 years for females. Hungary currently has 165 hospitals, with 70 beds and 40.9 medical
doctors per 10,000 people [56].
Among national characteristics pertaining to risk factors of S. suis infections, 28.65% of the
population lives in rural areas and around 5% of the population works in full-time agriculture [56,57].
According to the census data, 52.4% of the population is female [54]. Hungary has one of the highest
rates of people with type II diabetes, very high rates of smoking prevalence and one of the highest
rates of morbidity due to malignant diseases in Europe [54–57]. The total per capita consumption of
alcohol is estimated to be 11.4 L/year, which is much higher than the worldwide average [~6 L/year],
based on WHO criteria [58]. Meat consumption is estimated to be 65.04 kg/person annually (moderate),
out of which ~25 kg/person (i.e., 38.5%) is pork meat per capita [59]; however, this ratio was over
50% during the period between 2000 and 2010. In an attempt to boost domestic pork production and
consumption, the Hungarian government has cut the value-added tax (VAT; from 27% to 5%) on pork
offal and related products [60].
2.2. Data Collection
As a part of our study, data were collected from the Subcommittee on Gram-positive bacteria
of the National Bacteriological Surveillance (NBS) system on patients who had at least one positive
microbiological result for S. suis in a hospital (including intensive care units and departments
of traumatology, surgery, pediatrics, dermatology, ophthalmology, obstetrics and gynecology,
otorhinolaryngology, and head and neck surgery) in Hungary, between 1 January 2002 and 31
December 2019 (18-year-long period) [61]. The following anonymized data were exclusively collected
during the study: age at sample submission, gender, place of residence, type of sample(s) submitted for
microbiological analysis, results of microbiological analyses, and antimicrobial susceptibility testing.
2.3. Bacterial Identification, Antibiotic Susceptibility-Testing
Sample processing and microbial identification in the respective microbiology laboratories were
carried out according to guidelines for routine clinical bacteriology. Cerebrospinal fluid samples
and blood samples were taken for both clinical chemistry and microbiology. Blood culture samples
for microbiological analysis were inoculated into blood culture bottles and incubated in automated
blood culture systems. If the blood culture instrument reported a positive result, samples were
inoculated onto relevant agar media. In case of cerebrospinal fluid samples, enrichment broth
media were also used in addition to agar media. Latex agglutination-based rapid tests—aiming to
identify the main pathogens of bacterial meningitis from the cerebrospinal fluid—were also performed.
After 2013, several tertiary-care hospitals and specialized-care centers have introduced matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) into their diagnostic
workflow [62,63].
Antimicrobial susceptibility testing was performed by the disk diffusion method for penicillin (from
which, susceptibility to other β-lactams may be inferred), erythromycin, clindamycin, moxifloxacin,
tetracycline, and vancomycin. Inducible clindamycin resistance was detected using the D-test and
these strains were also reported as resistant [64]. The results were interpreted following the breakpoints
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for viridans streptococci approved by the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) for penicillin and other β-lactam antibiotics, clindamycin and vancomycin, Clinical and
Laboratory Standards Institute (CLSI) guidelines were used for erythromycin and tetracycline, while in
the case of moxifloxacin, S. pneumoniae breakpoints were used [4,15]. Intermediate results were grouped
with and reported as resistant.
2.4. Statistical Analysis
Due to the low number of relevant isolates, only descriptive statistical analyses were performed.
Categorical variables were summarized by frequencies and percentages, while continuous data were
presented as mean ± standard deviation (SD) and counts or percentages (%). All statistical analyses
were performed using Statistical Package for Social Science (SPSS) software (IBM SPSS Statistics for
Windows 24.0, IBM Corp., Armonk, NY, USA).
2.5. Ethical Statement
Data collection on anonymized patient affected by S. suis infections was in accordance with
ethical standards at the institutional and/or national research committees and with the 1964 Helsinki
Declaration and its later amendments.
3. Results
3.1. Epidemiology and Antibiotic Susceptibility of S. suis Infections in Hungary
During the 18-year study period (2002–2019) n = 74 S. suis strains were isolated from invasive
human infections in Hungarian hospitals (based on reports to the NBS), corresponding to 34 patients.
The number of affected patients was 1.89 ± 1.53/year (range: 0–5), which was consistent throughout
the study period; however, there were zero cases in 2007 and 2010, while peaks of n = 5 cases were
seen in 2014 and 2018, respectively. The temporal distribution of S. suis infections is presented in
Figure 1, while the spatial distribution of cases in Hungary is shown in Figure 2. The number of cases
was almost double as high in the second half (2011–2019) of the study period (12 vs. 22). The average
incidence of S. suis infections was 0.35/100,000 persons. The median age of affected patients in 57 years
(range: 21–91 years), while 20 out of 34 patients (58.8%; male-to-female ratio: 1.43) were males. Among
the indications listed for sample submissions, the most common was meningitis (n = 36, 48.6%),
followed by fever (n = 18, 24.4%), sepsis (n = 10, 13.5%), and other infectious processes (n = 10, 13.5%).
Immuno-suppression was verified in only 5 out of 34 patients, while a known history of contact with
pigs or other companion animals was noted only in 4 out of 34 patients.
Out of the n = 74 samples positive for S. suis, n = 47 (63.5%) were blood culture samples, n = 14
(18.9%) were cerebrospinal fluid samples, n = 6 (8.1%) were wound samples, while n = 7 (one abscess
sample, one bile samples, one inner ear aspirate, two pus samples and two intra-abdominal fluid
samples; 9.5%) were others. The incubation period usually ranged between <1 to 4.2 days. In case of
n = 7 patients, S. suis was simultaneously present in both their blood culture and cerebrospinal fluid
samples. During the analysis of susceptibility-testing results, only the first isolate per patient was
included: all the respective isolates were uniformly susceptible to β-lactam antibiotics and vancomycin
(34/34), while 14/34 of isolates were resistant to erythromycin and clindamycin, 10/34 of isolates were
resistant to moxifloxacin and 9/34 were resistant to tetracycline. Data on S. suis serotypes were only
available in the in case of the most recent 11 cases (including the three cases described in detail below):
n = 10 were the SS2, while n = 1 was the SS14 serotype.
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3.2.1. Case 1
At the Petz Aladár County Teaching Hospital in Gyo˝r in January 2018—in the midst of an influenza
epidemic—a male patient presented with symptoms of purulent meningitis, whose brief medical
history is described below: the 48-year-old male patient was admitted to the Emergency Department
(ED) after being transferred to the hospital by the National Ambulance Service from the patient’s
place of residence. The patient was admitted due to a headache; high fever (41 ◦C) and myalgia,
which presented two days before; and vomiting, diarrhea and aphasia, which presented one day
before hospital admission. The past medical history of the patient was unremarkable. The vital
signs of the patient were the following: 156/104 mmHg, pulse: 117/min, body temperature: 37.3 ◦C
(due to administration of antipyretic medication at home), oxygen saturation: 98%. Upon physical
examination, the patient was alert but disoriented, meningeal excitatory signs (Kernig, Brudzinski)
were positive. On admission, other abnormalities were not detected; a rash, bleeding, swollen or
painful joints were not seen. Among laboratory parameters, the WBC count of 25.6 G/L and the
CRP-levels of 162.4 mg/L were of interest. No abnormalities were seen on the chest X-ray or the
head CT. Subsequently, samples were taken for laboratory analysis: blood samples and cerebrospinal
fluid were sent to the Department of Clinical Chemistry, while two sets of blood culture bottles
and a cerebrospinal fluid sample was sent to the microbiology department for culture. During
the lumbar puncture, opalescent cerebrospinal fluid was observed, flowing at medium pressure.
The result of the examination of the cerebrospinal fluid at the Department of Clinical Chemistry was
the following: cell count: 750, protein: 3.5 g/L, glucose: 1.2 mmol/L. Rapid tests from the cerebrospinal
fluid, aiming to identify the main pathogens of bacterial meningitis (S. pneumoniae, S. agalactiae,
Haemophilus influenzae, Neisseria meningitidis A, C, Y, W135, N. meningitidis B, E. coli K1) showed a
negative result. A Gram-stained smear from the cerebrospinal fluid was observed under a microscope:
20–30 granulocytes and Gram-positive, spear-shaped diplococci were observed per field of view.
Based on the microscopic image, the pathogenic role of S. pneumoniae was suspected, but this was
not confirmed by the rapid latex agglutination test. Following the administration of dexamethazone,
empiric antibiotic therapy (ceftriaxone, ampicillin) was initiated at the ED, according to the protocol
for the treatment of community-acquired purulent meningitis, and then the patient was placed in the
Infectious Disease Ward. On the second day of treatment, an α-hemolytic Streptococcus was cultured
from both the blood culture samples and the cerebrospinal fluid. Identification was carried out using
an ID32 Strep (bioMérieux, Marcy-l’Étoile, France) semi-automatic identification system; the pathogen
has been successfully identified as S. suis. For verification purposes, the isolate was sent to the National
Institute of Public Health; the original identification was also verified by a MALDI-TOF MS system.
Antibiotic susceptibility testing of the isolate was carried out: the isolate was shown to be
susceptible to penicillin and ceftriaxone. Armed with susceptibility-results, the empiric ampicillin-
therapy was suspended and ceftriaxone monotherapy was initiated which lasted for 14 days.
Consultation with a cardiologist has excluded the possibility of endocarditis. Audiological examinations
were not carried out, as the patient did not have such symptoms. After the administration of the
antibiotic therapy, the patient’s complaints have disappeared, the laboratory parameters regressed,
and the control microbiological examinations (blood cultures, cerebrospinal fluids) were negative.
The isolate was found to be the SS2 serotype. No sequelae were observed either after discharging of the
patient or after follow-up examinations one month later. Given the role of S. suis in zoonosis, a detailed
heteroanamnesis revealed that the patient kept Mangalica (Mangalitsa or Mangalitza), a Hungarian
breed of domestic pigs, on his family farm and one of his hobbies included hunting. Two days before
he fell ill, he hunted down a wild boar and processed it in his own home.
3.2.2. Case 2
A 37-year old male patient—who was employed as a waste collector—was transferred from the
ED of the local hospital in Mohács to the Department of Neurology of the University of Pécs, due to
progressive loss of consciousness, headache, fever, numbness of the right arm and primary progressive
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aphasia. The patient’s past medical history was unremarkable, apart from known diagnoses of ulcus
duodeni and hypertension. Based on the reports of the ambulance staff, the socio-economic status of
the patient was low (in their apartment, a high degree of clutter and garbage was seen). The patient
showed meningeal excitatory signs (Kernig, Brudzinski) and presented with neck stiffness; thus,
blood cultures and cerebrospinal fluid samples were taken for microbiological analysis. During
laboratory analysis, inflammatory markers (C-reactive protein: 200 mg/L, WBC: 18,700/µL) were
elevated and 60,000–70,000/mm3 of granulocytes were counted in the cerebrospinal fluid. Results of
the latex-agglutination “meningitis” rapid tests were negative. Both samples types were positive for
an optochin-resistant, α-hemolytic Streptococcus, which was subsequently identified as Aerococcus
viridans by an API 20 Strep Kit (bioMérieux, Marcy-l’Étoile, France). As the patient did not have any
underlying illnesses that would point to the infectious role of A. viridans, the bacterial isolates were
sent to two partnering laboratories for further processing. In the Bay Zoltán Nonprofit Ltd. for Applied
Research (Budapest, Hungary), MALDI-TOF MS analysis was carried out, which has identified the
strain as S. suis with a reliable log score (>2.300). In the Department of Epidemiology and Microbiology,
Faculty of Veterinary Medicine, Szent István University (Budapest, Hungary), two methods were
utilized; namely, the Biolog MicroStation™ ID System (Hayward, CA, United States), and 16S rRNA
gene sequencing (Illumina, San Diego, CA, United States). While the former method was unable to
identify the isolate in question, 16S rRNA gene sequencing has found the highest (99%) match with
the sequences of S. suis. The isolate was the SS2 serotype of S. suis. After successful identification,
antibiotic susceptibility testing was carried out: the isolate was susceptible to β-lactam antibiotics,
therefore the empirical ceftriaxone therapy was continued and the patient’s condition improved rapidly.
The patient was discharged after 14 from his initial admittance to the ED. The patient denied any sort
of contact with pigs or other companion animals. During follow-up examinations, the patient was
assessed at the Department of Oto-Rhino-Laryngology, where the patient reported deafness on the
right side, and perceptional hearing loss on the left side. As a sequela, right-sided partial hearing loss
was observed by the patient, which has persisted in the subsequent follow-up examinations as well.
3.2.3. Case 3
A 34-year-old male patient was admitted to the ED of the Albert Szent-Györgyi Clinical Center in
Szeged, due to high fever (39.9 ◦C) and unconsciousness. In his past medical history, obesity (BMI > 30)
and splenectomy was recorded 10 years ago due to a motorway accident. The patient was employed
as a butcher in a local meatpacking plant, where he was reportedly injured on his hand by a sharp
fragment of a pork bone, which occurred one day before admission. On arrival, the obese (BMI > 30)
patient presented with no neck stiffness or meningism, nor peripheral stigmata of infective endocarditis.
The patient had a high fever, chills, abdominal pain and watery diarrhea at his home; family members
found the unconscious patient on the bathroom floor. XBLS (Extended Basic Life Support) and later
ALS (Advanced Life Support) were started because of circulatory and respiratory failure. The patient
was intubated and epinephrine was administered, which was followed by the return of spontaneous
circulation. Cranial and abdominal CT scans and pulmonary angiography were carried out to rule out
various pathologies. Cranial CT showed right-sided, multiple, acute ischemic lesions. On admission to
the ICU, the patient presented with severe hypotension, sinus tachycardia and high fever, even after the
administration of intravenous dopamine. Despite positive end-expiratory pressure (PEEP) appropriate
oxygenation could not be achieved and respiratory and metabolic acidosis, severe hypoglycemia and
hypokalemia were noted. Supportive therapy (K+-substitution, ventilation support and glucose) and
subsequent high-dose vasopressor therapy only led to minor improvements. Duplicate blood cultures,
urine samples, feces and sera for serology were taken and sent with urgency to the microbiology
laboratory. Leukocyte cell count and C-reactive protein were 17.0 × 109/L and 0.65 mg/dL, respectively.
Laboratory results confirmed disseminated intravascular coagulation (DIC; suspected by bleeding
from puncture sites and emergence of petechiae) and acute kidney and liver failure. The patient died
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from complications (DIC, multi-organ failure and acute respiratory distress syndrome) within 12 h of
hospital admission.
Post-mortem examination verified DIC and multiple organ damage, microthrombosis and necrosis,
predominantly in the lungs, liver, kidneys. The results of serology and microbiological analyses were
received after the patient had already passed away. S. suis was detected in the blood culture samples
previously submitted (time to positivity: 1 and 4 h, respectively), while viral serology only revealed a
past EBV infection. S. suis was identified by MALDI-TOF MS (Bruker Daltonics, Billerica, MA, USA),
with a reliable log score (>2.300). Identification was also complemented by 16S rRNA gene sequencing.
Sequencing of the 16S rRNA gene confirmed that the strain belonged to the species S. suis with 99%
nucleotide identity compared with GenBank accession no. NR036918, AF009487 and AM946016.
The isolate was found to be the SS2 serotype. The strain was susceptible to β-lactam antibiotics and
resistant to clindamycin, erythromycin and tetracycline. Resistance-determinants were verified using a
PCR assay, indicating that our isolate with the tet(Q) and erm(B) genes.
4. Discussion
S. suis is a Gram-positive, facultative anaerobic bacterium, which is commonly found in the
microbiota of pigs and they may also be found in other animals to a lesser extent [65]. The piglets may
be healthy carriers or they may be afflicted by the presence of these pathogens. S. suis is normally
found in the upper respiratory tract of pigs, mostly in the tonsils (tonsil carriage rate in piglets aged
4–6 months is around 32–50%), nasopharynx, gastro-intestinal, genital and alimentary tracts [66,67].
Transmission among pigs is generally the respiratory system in the form of direct nose-to-nose
contact (horizontal transmission); however, vertical transmission through the genital tract during
farrowing is also possible [68]. Susceptible animals may suffer from similar disease manifestations
(meningitis, septicemia, pneumonia, endocarditis, or polyarthritis) as their human counterparts and
the pathogenesis of the disease is also thought to be very similar [69]. Therefore, S. suis infections in
animals are an important economic burden to the livestock-breeding industry. There are continent-wide
programs aimed at the prevention of S. suis disease in livestock [70].
Infections caused by S. suis—which are mainly related to pigs—are causing zoonotic diseases
of increasing frequency worldwide. The first human case was reported in 1968, with sporadic cases
occurring worldwide in subsequent years. Nevertheless, the true significance of this zoonotic pathogen
has been demonstrated after multiple outbreaks in Asia (e.g., China, Vietnam) associated with S. suis
were reported [71]. Exporting pork goods (containing multiple S. suis serotypes) may lead to the
development of more virulent strains through recombination or the exchange of mobile genetic
elements between the local and foreign isolates [72]. A breach in the integrity of the skin is postulated to
be one of the main routes of infection in Western countries; however, the precise route of transmission
is not always identified [73]. Some cases have been linked to accidental inhalation of infected aerosols
from infected carcasses, though S. suis is also found in faces and fomites of infected animals [1,2,15,73].
The prevalence of S. suis infections in humans has shown a notable increase in the last decade, with
highest prevalence values in countries with a high pig density (i.e., Southeast Asia) [74]. There is a
wide clinical variation in the presentation of S. suis infections in humans, but meningitis and sepsis
are the most common and serious clinical manifestations of S. suis infections; these pathologies are
usually accompanied with hearing loss in the surviving patients (which was also demonstrated in
our Case 2) [75–77]. According to animal experiments, the human pathomechanism of hearing loss is
likely from the invasion of S. suis to the perilymph, via the cochlear aqueduct, resulting in suppurative
labyrinthitis [78]. This concomitant morbidity warrants the need of close monitoring and early adequate
care in meningitis patients; in addition, the invasive nature of S. suis serotype 2 may have an important
role in the development of these sequelae. The polysaccharide capsule containing sialic acid feature
makes the organism highly invasive in entering the bloodstream and penetrating the blood-brain
barrier [79]. One specific feature suggested for the European S. suis isolates is their predilection to
the meninges and their frequent involvement in the etiology of purulent meningitis [80]. In a report
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published by Mancini et al., the first fatal human case of S. suis streptococcal toxic shock syndrome
(STSS) in Italy was described and they have also published the draft genome of this strain. The patient
was a 55-year-old male with Hodgkin’s lymphoma and a previous splenectomy, who presented with
severe sepsis, DIC and MOF. The isolated strain from the blood culture samples was characterized by
microbiological and molecular methods: the strain was found to be serotype 2, sequence type 1, had a
plethora of virulence genes (mrp, epf, sly, arcA, ofs type 1 and cps2), a macrolide resistance determinant
(ermB) and a rare variant of tetracycline resistance, involving efflux pumps and ribosomal protection
(tet(O/W/32/O) and tet40) [81].
S. suis infections are not uncommon but, in Western countries, infections in humans are mostly
reported sporadically [15]. Unfortunately, only a few reports exist related to epidemiological data
on human S. suis infections from European countries (corresponding to the global prevalence by
~8–10%) [1,4]. There may be a correlation between European disease epidemiology and the reality that
the invasive and virulent SS2 is frequently found in pigs on the continent [82]. Interestingly, North and
Central American countries (USA, Canada, Mexico, Guatemala, Costa Rica and so on) reported the
lowest number of human cases, while reports on S. suis affecting pigs are most numerous in the United
States [25]. Some suggest strains in North America belonging to SS2 to be less virulent than strains in
Europe and Asia. [51]. The first publication in Europe was from Denmark [11]; nevertheless, cases have
been reported from various European countries including the United Kingdom [83], Germany [84],
Belgium [85], France [86], the Netherlands [87], Switzerland [88], Sweden [89], Spain [90], Portugal [91],
Italy [92], Greece [93], Austria [94], Hungary [95], Croatia [96] and Serbia [97] (it must be noted that
several of these reports are only available in their native languages). Most European cases of S. suis
infections in humans were reported from the Netherlands (n = 52), Poland (n = 22), France (n = 19),
Germany (n = 19), the United Kingdom (n= 19) and Denmark (n = 12), while zoonoses caused by
this pathogen occurred only sporadically in the remaining countries [1,2,25,51]. Surprisingly, no cases
have yet been published in Russia, the Czech Republic, Slovakia or Romania, despite the fact that
the economies of the previously mentioned four countries heavily rely on animal husbandry and
the production of pork meat [6]. Overall, the most prevalent clinical syndrome described in human
S. suis infections is meningitis (68.0%), followed by sepsis and toxic shock syndrome (25.0%), arthritis
(12.9%), endocarditis (12.4%) and endophthalmitis (4.6%) [1,4,38]. The most common corresponding
clinical symptoms of infection are generally similar to those of other bacterial pyogenic meningitis,
including include headache, fever, vomiting, subjective hearing impairment, positive meningeal sings,
the presence of skin rash, bacteremia, shock, acute renal failure, respiratory distress, MOF, changes
in the common laboratory parameters (leukocytes, platelets, C-reactive protein) and findings in the
CSF [1,4,38,51–53]. The onset of the disease is usually 1–4 days from coming in contact with the
pathogen, and depending on the disease manifestation, the duration of illness may range between
1 and 24 days. If the patient is admitted, the length of their hospital stay is usually around two
weeks (range: 1–46 days) [1,2,4,38]. The therapeutic approach of invasive S. suis infections is similar
to those for other causes of bacterial meningitis/sepsis. Empiric antibiotic therapy (ceftriaxone ±
vancomycin) should be initiated without delay, which must be re-evaluated after susceptibility-testing
results become available [1,4,15,38]. Several case reports highlighted advantageous clinical outcomes
and lower chance of hearing impairment if adjunctive dexamethazone is administered to the patients.
In severe cases, renal replacement therapy, assisted ventilation and circulatory support must also be
provided. Among recovered patients, 39% (31.0–47.8%) experience hearing loss, which is sensineural
and affects the high frequency range; in ~75% of these cases, the hearing loss is irreversible [1,4,38,51–53].
Twenty-three percent (15.6–32.0%) of patients are also affected by vestibular dysfunction, which also
significantly affects the quality of life of the individual [38].The low number of published human cases
in these countries is presumably due to underdiagnosis and unawareness of the disease because the
organism is often misidentified by microbiologists, which results in delay or inadequate treatment [25].
Misidentification may be very common in case of these bacteria; S. suis is frequently misidentified as
S. viridans, while inappropriate results as S. bovis, S. pneumoniae, E. faecalis and S. acidominimus may
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also commonly occur [1,2,25,51,98]. In the case report of Tarini et al., the causative agent of meningitis
for a 50-year-old male patient was identified as S. mitis with a 99% probability (based on the VITEK
2 Compact ID/AST system), while sequencing results from cerebrospinal fluid confirmed S. suis as
the true pathogen [99]. The increasing use of modern diagnostic tools (e.g., PCR, MALDI-TOF MS)
and methods available for use directly from clinical specimens may further aid the identification
biochemically inactive or unreliably-identified isolates [100,101]. A very recently published report by
Olearo et al. showed the first imported human case of S. suis infection in Switzerland: a 45-year-old
woman bought and consumed raw pork meat imported from a small local farm in Moldova 24 h
before flying back to Geneva, Switzerland. She was admitted to the local hospital in septic shock
three days after ingestion of the pork meat and S. suis strains were isolated and next identified by 16
rDNA sequencing from blood cultures. Later on, the serotyping of the S. suis strain was identified
as serotype 14, based on a high-resolution melting assay. According to EUCAST breakpoint criteria,
the susceptibility tests revealed multi-susceptible isolates; subsequently, empiric antibiotic therapy
(ceftriaxone) was de-escalated (to penicillin G for 22 days) until the patient has left the hospital [102].
Based on sequencing analysis, this human strain is not genetically close to strains originating from
swine previously isolated in the country. The strain was sequence type ST1 (PubMLST ID: 2250),
which was new type from Switzerland. The average nucleotide identity of this strain was between
94.0% and 99.9%, when compared to previously deposited full sequences of S. suis genomes [102].
As occupational contact with pigs or pork meat is one of the principal factors to consider
(pig-related occupation was noted in ~38%, while other contact with pigs was reported in ~34% of
published cases [4]), upholding the appropriate conditions of slaughterhouses is of utmost importance.
Slaughterhouses are a good examples of epidemiological observatories, encompassing many aspects
of the “One Health” perspective: they may be a source of infection in animals (resulting in local
outbreaks and loss of income) and they have a role in facilitating zoonotic transmission from pigs
to humans; thus, enforcing the compliance with national/international animal husbandry standards,
environmental hygiene, cleaning and sanitation practices is crucial from a public health point of view.
Continuous surveillance on S. suis carriage, serotype-distribution and the prevalence of associated
diseases is also warranted among animals. From the human perspective, compliance with workplace
regulations, the medical assessment of employees and education on workplace-related health risks is
a responsibility of occupational medicine [1,2,4,15,25,35,41,53]. While swine-related occupancy is a
well-known risk factor for human infections, interestingly, exposure to pigs or pork meat is not present
in many of the published cases from European countries [1,2,15,25,41,53,81–97]. Although substantial
new data on the incidence, clinical and microbiological characteristics, and risk factors for S. suis
infection has been accumulated during recent years, there is not enough evidence to even estimate the
prevalence of this infection on the continent. It was proposed that the principal transmission routes
may significantly vary in Asian countries (oral transmission, through ingestion of raw meat) compared
to the European region (transmission through injuries during meat processing) [1,2,15,25,41,53,81–97].
In fact, raw pork consumption was associated with more than four times (the reported odds ratio in
the publication was 4.63) the risk of developing a S. suis infection (confidence interval: 2.94–7.29) [41].
However, in the report published by Manzin et al., a 68-year-old Italian patient developed a severe case
of meningitis without having any contact with swine, other animals or any animal products; it was
later discovered that the patient had an advanced-stage malignancy [103]. In most European countries,
the infection rates among the exposed groups are poorly known as the diseases caused by S. suis
are not notifiable, and only the United Kingdom and France consider S. suis infections in humans as
an industrial-risk disease (affecting farmers, veterinarians, butchers, food processing workers and
so on) [1,2,15,25,53,81–97]. While the colonization rate of S. suis in swine and wild boars has been
extensively described (85–100%), there are very few reports on the human colonization rate with S. suis;
most studies report on the risk-group population of people handling pork meat, with the colonization
rates ranging between 0–10% [1,2,15–17,23–35].
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The aim of our present study was to assess the spatio-temporal trends of invasive S. suis infections
in Hungary between 2002 and 2019, based on the data available from the National Bacteriological
Surveillance System. This is, to date, the first comprehensive study of human S. suis infections
from Hungary, as even case reports were available only from microbiology and infectious disease
congresses throughout Hungary. Overall, 34 patients were affected by invasive S. suis infections
throughout the 18-year-long study period. In addition, we have presented three distinct cases,
which showed the plethora of possible outcomes of S. suis infections: a patient recovered without
any long-term consequences, one patient reported hearing loss as a long-term sequelae, while a
third, splenectomised young patient has died suddenly and quickly from infectious complications.
The relatively low frequency (2–3 cases/year) of invasive S. suis infections were highlighted in a period
close to 20 years, despite the special characteristics of the country (being extensive consumers of alcohol
and hard drinks due to several national traditions, an extensive agricultural sector which employs
a relatively high proportion of the population, high levels of pork meat export and consumption).
In addition, the prevalence of many underlying conditions responsible for higher risks of infections and
immunosuppression (diabetes mellitus, alcoholism, smoking, obesity, cancers) are also pronounced
in this country. Nevertheless, the average rate of infections was much higher than the reported
prevalence in most Western European countries (0.35 vs. 0.01–0.10/100,000 persons). The geographical
distribution did not show any correlation with the population of the respective towns, where the
strains were isolated; however, most of the cases originated from provincial areas. Although older male
patients were more likely to be affected, overwhelming generalizations on the risk population cannot
be made, as there were persons from very different backgrounds, vocations and age groups among
affected patients. Global efforts to develop effective vaccinations against invasive S. suis infections
need to be strengthened, both for human subjects in the risk of environmental exposure (especially
splenectomized patients), both for animals to reduce the economic burden of these infections in animal
husbandry [104,105]. Bojarska et al. published one of the only available long-term reports on the
prevalence of S. suis in East-Central Europe: as a part of the activities of the National Reference Centre
for Bacterial Meningitis (NRCBM) in Poland between 2000–2013, n = 21 patients were affected by
invasive S. suis infections [106]. Interestingly, during re-identification in the reference center, it was
found that 48% of isolates were initially misidentified by the submitting microbiological laboratories.
Most of the isolates were serotype 2, around half of the isolates were biofilm-producers and genes
encoding for virulence factors (DNase, suilysin, extracellular protein factor, fibronectin-binding protein,
muramidase-released protein, surface antigen one, enolase, serum opacity factor and pili) important in
invasive disease were ubiquitous in these isolates. Their study concluded that the prevalence of S. suis
diseases is most likely to be underestimated, as the country possesses a well-developed pork industry
with a high output (over 10 million units) [106].
5. Conclusions
The results of our study highlight that clinicians and microbiologist need to be vigilant even
in nonendemic areas, especially if the patients have a history of occupational hazards or having
close contact with infected pigs even if they are immunocompetent. Educational efforts are needed
among patients at increased infection risk, such as splenectomized patients or patients receiving
immunosuppressive medication; these patients should avoid direct pig or pork contact when skin
lesions—particularly on the hands—are present. During clinical situations, it is important to administer
adequate therapy for patients with histories and symptoms suggestive of S. suis infections, even if
laboratory verification of the diagnosis is not yet available or in case of negative cultures (due to
previous administration of antimicrobials or misidentification). Infection prevention and control
measures are currently the “best-buy” method available to control disease transmission, at least until
an effective vaccine becomes available. From a public health perspective, educational campaigns on
food safety could be an effective way to increase the understanding of the public regarding this illness,
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especially in regions, where there is strong association between traditional domestic pig slaughter and
consumption of raw meat and meat products.
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